Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study
Study Drug Administration:
If patient is found to be eligible to take part in this study, on Day 1, cidofovir will be
put into the bladder through the foley catheter. The catheter will be clamped shut for 2
hours to keep the drug inside patient's bladder. After 2 hours, the catheter will be
unclamped so that the drug may drain out. If patient was receiving bladder irrigation (where
the bladder is flushed with water) as therapy for hemorrhagic cystitis, this therapy will be
restarted after their dose of cidofovir.
Pharmacokinetic (PK) and Pharmacodynamic (PD) Testing:
On Day 1, blood (about 2 teaspoons each time) will be drawn for PK and PD testing before the
dose, 2 times during the dose, and 4 more times over the next 20 hours (+/- 1 hour) after
the dose. PK testing measures the amount of study drug in the body at different time
points. PD testing measures how the level of study drug in the body may affect the disease.
Virus Testing:
During this study, extra urine and leftover blood will be collected and used for research to
test for certain viruses, including the type of infection patient had when they joined this
study.
Before and after the cidofovir dose on Day 1, and again on Day 4, urine will be collected
for virus testing.
Any blood left over from Day 1 testing will also be used for virus testing.
Length of Study Participation:
Patient's active study participation will be over after the Day 14 follow-up visit (below).
If patient experiences a side effect, the study staff will continue checking their medical
records until the side effect becomes stable or gets better.
Follow-Up:
On Days 3 and 7, blood (about 2 teaspoons) will be drawn for routine tests.
On Day 7 (+/- 2 days):
- Patient's vital signs will be measured, and they will be asked about any symptoms they
may be having.
- Blood (about 1 teaspoon) will be drawn for routine tests.
- Blood (about ½ teaspoon) will be drawn for PK testing.
- Urine will be collected for routine tests.
On Day 14 (+/- 2 days):
- Patient will be asked about any symptoms they may be having.
- Blood (about ½ teaspoon) will be drawn for PK testing.
- Urine will be collected for routine tests.
On Day 30 (+/- 2 days), patient will be contacted by phone and asked about any side effects
they may be having. This call will take about 10 minutes.
This is an investigational study. Cidofovir given by injection is commercially available
and FDA approved to treat CMV in patients with HIV. Its use in this study is
investigational.
Up to 6 patients will take part in this study. All will be enrolled at MD Anderson.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Systemic Absorption of Cidofovir
Systemic absorption of drug evaluated during and after intravesical administration. Blood collected for each sample in the following schedule: T0 (pre-instillation) 1 hour (after instillation) 2 hours (after instillation-at the time of de-clamping) 4 hours +/- 1 hour (after instillation) 14 hours +/- 1 hour (14 hours after instillation or 12 hours from de-clamping). 24 hours +/- 1 hour after instillation to ensure complete characterization of cidofovir elimination.
7 days
No
Roy F. Chemaly, MD, MPH, MBA
Principal Investigator
M.D. Anderson Cancer Center
United States: Food and Drug Administration
2012-0903
NCT01816646
September 2013
Name | Location |
---|---|
University of Texas MD Anderson Cancer Center | Houston, Texas 77030 |